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Abstract
Background: Synthetic peptides containing the RGD sequence inhibit integrin-related functions
in different cell systems. Here, we investigated the effects of synthetic Arg-Gly-Asp-Ser (RGDS)
peptide on key inflammatory responses to intratracheal (i.t.) lipopolysaccharide (LPS) treatment
and on the integrin signaled mitogen-activated protein (MAP) kinase pathway during the
development of acute lung injury.
Methods: Saline or LPS (1.5 mg/kg) was administered i.t. with or without a single dose of RGDS
(1, 2.5, or 5 mg/kg, i.p.), anti-αv or anti-β3 mAb (5 mg/kg, i.p.). Mice were sacrificed 4 or 24 h post-
LPS.
Results:  A pretreatment with RGDS inhibited LPS-induced increases in neutrophil and
macrophage numbers, total protein levels and TNF-α and MIP-2 levels, and matrix
metalloproteinase-9 activity in bronchoalveolar lavage (BAL) fluid at 4 or 24 h post-LPS treatment.
RGDS inhibited LPS-induced phosphorylation of focal adhesion kinase and MAP kinases, including
ERK, JNK, and p38 MAP kinase, in lung tissue. Importantly, the inhibition of the inflammatory
responses and the kinase pathways were still evident when this peptide was administered 2 h after
LPS treatment. Similarly, a blocking antibody against integrin αv significantly inhibited LPS-induced
inflammatory cell migration into the lung, protein accumulation and proinflammatory mediator
production in BAL fluid, at 4 or 24 h post-LPS. Anti-β3 also inhibited all LPS-induced inflammatory
responses, except the accumulation of BAL protein at 24 h post-LPS.
Conclusion: These results suggest that RGDS with high specificity for αvintegrins attenuates
inflammatory cascade during LPS-induced development of acute lung injury.
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Background
Acute lung injury is characterized by an intense pulmo-
nary inflammatory response, with neutrophil recruit-
ment, interstitial edema, disruption of epithelial integrity,
and parenchymal injury [1]. The migration of leukocytes
to inflamed sites depends on the interactions of various
integrins expressed on leukocytes with the Ig superfamily
of cell adhesion molecules (ICAM-1 and ICAM-2) present
on the endothelium and with the extracellular matrix lig-
ands. Multiple integrins participate in neutrophil migra-
tion into the lung during LPS-induced lung injury. In
addition to β2 integrin (CD18), α4β1 and α5β1 integrins
also contribute to β2-independent neutrophil migration
during pulmonary inflammation [2]. However, neither β2
blockade nor α4  plus  α5 blockade reduced neutrophil
accumulation in the parenchyma and only minimally in
the airspaces [2]. These findings suggest that there are
functionally redundant alternative integrin pathways that
signal neutrophil recruitment to the lung and inflamma-
tory responses.
Many members of the integrin family, such as α5β1, αIIβ3,
αvβ3, αvβ6, α8β1, αvβ1, αvβ5, and αvβ8, recognize the Arg-
Gly-Asp (RGD) motif within their ligands [3], which
include fibronectin, fibrinogen, vitronectin, von Wille-
brand factor and collagens [4]. Synthetic peptides con-
taining the RGD sequence have been shown to compete
with adhesive proteins for binding to these integrin recep-
tors [5], and thus, inhibit integrin-related functions in dif-
ferent cell systems. This suggests the possibility that
therapeutic RGD-containing integrin ligands could be
developed to ameliorate inflammatory cascades, specifi-
cally those that cause the migration and activation of leu-
kocytes.
Several previous reports suggest the possibility that RGDS
alters systemic inflammation. RGDS (i.p.) effectively
inhibits collagen-triggered activation of leukocytes and
platelets, such as aggregation and oxygen radical produc-
tion [6]. Koning et al. [7] demonstrated binding of RGD
peptide to proliferating vascular endothelial cells in LPS-
induced inflammation in rats. Moreover, RGD peptide
inhibits the expression of inflammatory cytokines, iNOS,
and MMP-9 in rat liver after cold ischemia/reperfusion
injury [8]. However, the local effect of RGDS on pulmo-
nary inflammation has not been evaluated.
The inhibitory effect of RGD peptide on LPS-induced
mitogen-activated protein (MAP) kinase activity and TNF-
α production was shown in RAW 264.7 cell model, sug-
gesting that LPS-induced integrin signaling converges on
MAP kinases [9]. Here, we evaluated the effects of RGDS
peptide on the pulmonary inflammatory responses,
including leukocyte migration into the lungs, damage to
the lung blood-gas barrier, and proinflammatory media-
tor production following i.t. LPS treatment. Furthermore,
we also examined the effects of RGDS on the integrin sig-
naled MAP kinase pathway during the development of
acute lung injury.
Materials and methods
Reagents
LPS (Escherichia coli lipopolysaccharide, 055:B5), Arg-Gly-
Asp-Ser (RGDS) and Arg-Gly-Glu-Ser (RGES) were pur-
chased from Sigma (St. Louis, MO). The antibodies used
in this study were: anti-integrin αv(RMV-7) mAb [10],
anti-integrin β3 (HMβ) mAb (BioLegend, San Diego CA)
[11], anti-rabbit phospho ERK/ERK, anti-rabbit phospho
JNK/JNK, and anti-rabbit phospho-p38 MAP kinase/p38
MAP kinase (New England Biolabs, Beverly, MA), and
anti-phospho-focal adhesion kinase (FAK) (pY397)/anti-
FAK (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
Animal protocols
Specific, pathogen-free male BALB/C mice (Daehan
Biolink Co. Eumsung-Gun, Chungbuk, Republic of
Korea) weighing 19–21 g were used in all experiments.
The Animal Care Committee of the Ewha Medical
Research Institute approved the experimental protocol.
Mice were cared for and handled in accordance with the
National Institutes of Health (NIH) Guide for the Care
and Use of Laboratory Animals.
Mouse pharyngeal aspiration was performed as described
by Rao et al. [12]. Animals were anesthetized with a mix-
ture of ketamine and xylazine (45 mg/kg and 8 mg/kg,
i.p., respectively). Test solution (30 μl) containing LPS
(1.5 mg/kg) was placed posterior in the throat and aspi-
rated into the lungs. Control mice were administrated
sterile saline (0.9% NaCl). Animals were administered
with RGDS or RGES peptide (1, 2.5 or 5 mg/kg, i.p.) once
one hour before LPS treatment and sacrificed 4 h post-LPS
[13,14]. Animals were also administered RGDS or RGES
peptide (5 mg/kg, i.p.) once at different time points (1 h
before or 2 h after LPS treatment) and sacrificed 24 h post-
LPS. In addition, animals were administered with αvβ3-
blocking mAbs, anti-αv, or anti-β3 (5 mg/kg, i.p.) once 1 h
before and sacrificed 4 h post-LPS. Animals administered
with these mAbs 2 h after LPS treatment were sacrificed 24
h post-LPS [15].
Isolation of bronchoalveolar lavage (BAL) cells, lung tissue, 
and cell counts
BAL was performed through a tracheal cannula using 0.8
ml aliquots of ice-cold Ca2+/Mg2+-free phosphate-buff-
ered medium (145 mM NaCl, 5 mM KCl, 1.9 mM
NaH2PO4, 9.35 mM Na2HPO4, and 5.5 mM dextrose; at
pH 7.4) for a total of 2.4 ml for each mouse. Cell counts
were determined using an electronic Coulter Counter fit-
ted with a cell sizing analyzer (Coulter Model ZBI with aRespiratory Research 2009, 10:18 http://respiratory-research.com/content/10/1/18
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channelizer 256; Coulter Electronics, Bedfordshire, UK),
as described by Lane and Mehta [16]. Neutrophils and
macrophages were identified by their characteristic cell
diameter [17].
Measurement of total protein in BAL samples
BAL protein concentration was used as an indicator of
blood-pulmonary epithelial cell barrier integrity [18].
Total protein was measured using the method devised by
Hartree [19], using bovine serum albumin as a standard.
TNF-α and macrophage inflammatory protein (MIP)-2 
measurements
First BAL fluid was assayed using TNF-α and MIP-2
enzyme-linked immunosorbent assay (ELISA) kits (R&D
Systems, Minneapolis, MN) according to the manufac-
turer's instructions. Concentrations of TNF-α, and MIP-2
were determined as picograms per milliliter based on the
appropriate standard curve.
Zymographic analysis of matrix metalloproteinase-9 
(MMP-9)
The gelatinolytic activities of BAL fluid samples were
determined by zymography using gelatin copolymerized
with acrylamide, as described previously [20]. Clear
zymogram bands were photographed using negative
Polaroid 665 film. MMP-9 activity was quantified by den-
sitometry using an UltroScan XL laser densitometer (LKB,
Model 2222-020).
Western blot analysis
Lung tissue homogenate was separated on 10% SDS-poly-
acrylamide gels. Separated proteins were electrophoreti-
cally transferred onto nitrocellulose paper and blocked for
1 h at room temperature with Tris-buffered SAL contain-
ing 3% BSA. Membranes were then incubated with the
indicated Abs and visualized by chemiluminescence
(ECL).
Fibrinogen binding assay
Adherent cells (> 95% alveolar macrophages) were incu-
bated in 100 μl DMEM containing 80 μg/ml fibrinogen
conjugated to Alexafluor-488, 2 mM CaCl2, and 4 mg/ml
BSA for 20 min [13]. Cells were then resuspended in a fix-
ation solution. Nuclei were stained with Hoechst no.
33258 (5 μg/ml, Calbiochem) for 10 min and slides were
then mounted. Images were collected using an LSM Image
Examiner on a confocal laser scanning microscope (LSM-
5 Pascal Exciter, Carl Zeiss, Germany).
Lung histology
Lungs were fixed with 10% buffered formalin at room
temperature for 48 h, dehydrated, and embedded in par-
affin. Sections (4 μm) were stained with hematoxylin and
eosin (H&E). Light microscopic analysis of lungs was per-
formed by blinded observation.
Statistical analysis
Values are expressed as means ± SEM. Inter-group com-
parisons were performed using one-way ANOVA followed
by Tukey's post hoc test. Statistical significance was set at P
< 0.05.
Results
Effects of RGDS peptide on the recruitment of 
inflammatory cells to lungs
The neutrophil cell numbers in BAL fluid increased at 4
and 24 h after i.t. LPS (1.05 ± 0.06 × 105/ml and 9.10 ±
0.43 × 105/ml, respectively) (Figures 1A and 1B). RGDS
(1, 2.5, or 5 mg/kg, i.p., 1 h before LPS) inhibited these
neutrophil increases 4 h post-LPS in a dose-dependent
manner (Figure 1A). Peak inhibition of 79% was observed
at 5 mg/kg. At 24 h post-LPS, we evaluated and compared
the inhibitory effects of RGDS (5 mg/kg) on inflammatory
cell migration when administered at different times, i.e.,
at 1 h before or 2 h after LPS (Figure 1B). Interestingly, the
inhibitory effect of RGDS on LPS-induced neutrophil
increases 24 h post-LPS was similar when administered at
these times (58 and 62% vs. LPS treated animals, respec-
tively).
Macrophage numbers in BAL fluid were unchanged at 4 h
post-LPS (Figure 1C), but were increased 2.5-fold at 24 h
post-LPS (1.04 ± 0.08 × 105/ml) (Figure 1D), and RGDS
treatment 1 h before or 2 h after LPS significantly inhib-
ited this increase. Moreover, the inhibitory effects of
RGDS were not significantly different (89 and 88% when
administered at these times vs. LPS treated animals,
respectively, p < 0.05) (Figure 1D). LPS+RGES (a negative
control) or saline+RGDS did not affect neutrophil and
macrophage cell numbers compared with LPS- or saline-
treated mice, respectively.
Histological lung sections obtained 24 h post-LPS con-
firmed BAL findings. H&E sections of lungs fixed with
paraformaldehyde revealed similar reductions in peri-
broncheal and intraalveolar infiltration of neutrophils in
lungs treated with RGDS at different times (Figure 2).
Effect of RGDS on protein levels in BAL fluid
LPS treatment significantly increased protein content in
BAL fluid at 4 and 24 h post-LPS, by 1.5- and 2.6-fold,
respectively, compared with saline treated controls (Fig-
ures 3A and 3B). RGDS (2.5 or 5 mg/kg, 1 h before LPS)
significantly decreased protein levels at 4 h post-LPS by 70
and 73%, respectively (p < 0.05) (Figure 3A). At 24 h post-
LPS, RGDS treatment 1 h before or 2 h after LPS, similarly
and significantly inhibited this LPS-induced BAL protein
increase by 62, and 64% vs. LPS, respectively (p < 0.05)Respiratory Research 2009, 10:18 http://respiratory-research.com/content/10/1/18
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Effects of RGDS peptide on LPS-induced increases in neutrophil (A, B) and macrophage (C, D) numbers in bronchoalveolar lav- age (BAL) fluid Figure 1
Effects of RGDS peptide on LPS-induced increases in neutrophil (A, B) and macrophage (C, D) numbers in 
bronchoalveolar lavage (BAL) fluid. Where indicated, mice were administered i.p. RGDS (1, 2.5 or 5 mg/kg) or RGES (5 
mg/kg, a negative control) once 1 h before LPS treatment and sacrificed 4 h post-LPS. Mice were also administered these pep-
tides (5 mg/kg, i.p.) once 1 h before or 2 h after LPS and sacrificed 24 h post-LPS. Values represent means ± SEM of 5 mice per 
group. *Significantly different from saline treated controls, p < 0.05; +significantly different from animals treated with LPS only, 
p < 0.05.Respiratory Research 2009, 10:18 http://respiratory-research.com/content/10/1/18
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(Figure 3B). LPS+RGES or saline+RGDS had no effect on
protein accumulation compared with LPS- or saline-
treated mice, respectively.
Effects of RGDS on TNF-α and MIP-2 levels, and MMP-9 
activity
TNF-α, MIP-2, and MMP-9 are representative proinflam-
matory mediators, which play major roles in neutrophil
influx and lung damage. TNF-α production and MMP-9
expression require integrin signaling, as demonstrated by
in vitro inflammatory cell models [21-26]. Here, we eval-
uated the effects of RGDS on these proinflammatory
mediators in BAL fluid. As shown in Figures 4A and 4B,
RGDS administered 1 h before LPS inhibited LPS-induced
increases in TNF-α and MIP-2 levels in BAL fluid at 4 h
post-LPS. Moreover, these inhibitions were in dose-
dependent and peaked at 5 mg/kg when these inhibitions
of TNF-α and MIP-2 levels were 47 and 60%, respectively.
At 24 h post-LPS, LPS-induced TNF-α levels in BAL fluid
were decreased by a fifth of those at 4 h post-LPS and MIP-
2 levels were decreased to saline control (data not shown).
Pre- or posttreatment with RGDS (5 mg/kg) significantly
inhibited LPS-induced TNF-α levels by 78 and 53%,
respectively (Figure 4D).
BAL fluid was also analyzed for evidence of MMP-9 activ-
ity by gelatin zymography. MMP-9 activity increased 7.7-
and 8.0-fold vs saline treated controls at 4 and 24 h post-
LPS, respectively. RGDS (2.5 or 5 mg/kg, 1 h before LPS)
significantly inhibited LPS-induced MMP-9 activity in
BAL fluid 4 h post-LPS (by 59 and 91%, respectively (p <
0.05) (Figure 4C). Pre- or posttreatment with RGDS (5
mg/kg) significantly inhibited LPS-induced MMP-9 activ-
ity by 83 and 70%, respectively, 24 h post-LPS (Figure 4E).
TNF-α and MIP-2 levels and MMP-9 activity were similar
in samples obtained from LPS and LPS-RGES treated ani-
mals at 4 or 24 h post-LPS.
Reduction in LPS-induced lung inflammation by RGDS Figure 2
Reduction in LPS-induced lung inflammation by RGDS. Mice were administered RGDS (5 mg/kg, i.p.) once 1 h before 
or 2 h after LPS and were sacrificed 24 h post-LPS. Lung sections were H&E stained, as described in Methods. Representative 
staining from 5 mice per group are shown.Respiratory Research 2009, 10:18 http://respiratory-research.com/content/10/1/18
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Effects of RGDS on the activation of integrin signaling and 
MAP kinases
In vitro inhibition of integrin signaling by RGD peptide
has been reported to decrease LPS-induced MAP kinase
activity and TNF-α production in macrophages [9]. To
investigate the functional link between integrin signaling
and LPS-induced MAP kinase activation during the devel-
opment of acute lung injury, we evaluated the inhibitory
effect of RGDS on LPS-induced FAK phosphorylation in
lung tissue. RGDS treatment 1 h before LPS completely
inhibited LPS-induced this kinase phosphorylation at 4 h
post-LPS (Figure 5A). At 24 h post-LPS, pre- or posttreat-
ment with RGDS also completely inhibited LPS-induced
FAK phosphorylation with similar potencies (Figure 5B).
We also examined the fibrinogen binding activity of alve-
olar macrophages, because fibrinogen is a specific and
physiologic ligand for activated integrin complexes,
including  αvβ3 [27]. As was expected, alveolar macro-
phages from mice treated with LPS were found to have
increased fibrinogen binding activity in many confocal
microscope fields, and RGDS treatment 1 h before or 2 h
after LPS suppressed this activity at 4 or 24 h post-LPS,
respectively (Figures 5C and 5D). These findings indicate
that RGDS inhibits LPS-induced integrin signaling during
the development of lung injury.
Figure 6 presents LPS-induced MAP kinase phosphoryla-
tion data in lung tissue at 4 or 24 h post-LPS, which con-
curs with the findings of our previous study [28,29].
Phosphorylation of ERK and JNK substantially were
increased 4 h post-LPS, and were either maintained (ERK)
(Figures 6A and 6B) or further increased (JNK) (Figures
6C and 6D). p38 MAP kinase phosphorylation substan-
tially increased at 4 h and this phosphorylation level was
Effects of RGDS on LPS-induced increases in total protein levels in BAL fluid Figure 3
Effects of RGDS on LPS-induced increases in total protein levels in BAL fluid. Where indicated, mice were adminis-
tered i.p. RGDS (1, 2.5 or 5 mg/kg) or RGES (5 mg/kg) once 1 h before LPS and sacrificed 4 h post-LPS (A). Mice were also 
administered these peptides (5 mg/kg, i.p.) once 1 h before or 2 h after LPS and were sacrificed 24 h post-LPS (B). Values rep-
resent means ± SEM of 5 mice per group. *Significantly different from saline treated controls, p < 0.05; +significantly different 
from animals treated with LPS only, p < 0.05.Respiratory Research 2009, 10:18 http://respiratory-research.com/content/10/1/18
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Effects of RGDS on LPS-induced TNF-α and MIP-2 productions, and on MMP-9 activity Figure 4
Effects of RGDS on LPS-induced TNF-α and MIP-2 productions, and on MMP-9 activity. Where indicated, mice 
were administered i.p. RGDS (1, 2.5 or 5 mg/kg) or RGES (5 mg/kg) once 1 h before LPS treatment and sacrificed 4 h post-LPS. 
Mice were also administered these peptides (5 mg/kg, i.p.) once 1 h before or 2 h after LPS and were sacrificed 24 h post-LPS 
(B). TNF-α and MIP-2 levels in BAL fluid samples were quantified using enzyme-linked immunosorbent assays (A, B, D). Gelati-
nolytic activity in BAL fluid samples (C, E). Samples were analyzed by zymography followed by scanning densitometry. The 92-
kD genolytic bands corresponded to MMP-9. Densities are expressed as percentages versus saline treated controls. Values 
represent means ± SEM of results from 5 mice per group. *Significantly different from saline treated controls, p < 0.05; +signif-
icantly different from animals treated with LPS only, p < 0.05.Respiratory Research 2009, 10:18 http://respiratory-research.com/content/10/1/18
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Effects of RGDS on FAK phosphorylation in lung tissue (A, B), and fibrinogen binding activity in alveolar macrophages (C, D) Figure 5
Effects of RGDS on FAK phosphorylation in lung tissue (A, B), and fibrinogen binding activity in alveolar mac-
rophages (C, D). Where indicated, mice were administered RGDS or RGES (5 mg/kg, i.p.) once 1 h before LPS treatment 
and sacrificed 4 h post-LPS. Mice were also administered this peptide (5 mg/kg, i.p.) once 1 h before or 2 h after LPS and sacri-
ficed 24 h post-LPS. (A, B) Western blotting with each anti-specific (phospho) FAK Ab was performed on lung tissue homoge-
nates. Relative values for phosphorylated FAK versus FAK are indicated below the gel. Values represent means ± SEM of 5 
mice per group. *Significantly different from saline treated controls, p < 0.05; +significantly different from animals treated with 
LPS only, p < 0.05. (C, D) Alveolar macrophages were incubated with fibrinogen conjugated to Alexafluor-488 for 20 min. 
After exposure to fibrinogen for 20 min, cells were fixed and then analyzed by confocal fluorescence microscopy. The results 
are representative results obtained from 5 mice per group.Respiratory Research 2009, 10:18 http://respiratory-research.com/content/10/1/18
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Effects of RGDS on phosphorylation of ERK1/2 (A, B), JNK1/2(C, D) and p38 MAP kinase (E, F) in lung tissue Figure 6
Effects of RGDS on phosphorylation of ERK1/2 (A, B), JNK1/2(C, D) and p38 MAP kinase (E, F) in lung tissue. 
Where indicated, mice were administered RGDS or RGES (5 mg/kg, i.p.) once 1 h before LPS treatment and sacrificed 4 h 
post-LPS. Mice were also administered these peptides (5 mg/kg, i.p.) once 1 h before or 2 h after LPS and sacrificed 24 h post-
LPS. Western blotting was performed with each anti-specific (phospho) Ab on lung tissue homogenates. Relative values for 
phosphorylated MAP kinase versus MAP kinase, respectively, are indicated below the gel. Values represent means ± SEM of 5 
mice per group. *Significantly different from saline treated controls, p < 0.05; +significantly different from animals treated with 
LPS only, p < 0.05.Respiratory Research 2009, 10:18 http://respiratory-research.com/content/10/1/18
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slightly reduced 24 h post-LPS (Figures 6E and 6F). RGDS
treatment 1 h before LPS significantly suppressed LPS-
induced phosphorylation of ERK, JNK and p38 MAP
kinase 4 h post-LPS. Pre- or posttreatment with RGDS also
inhibited all three MAP kinase phosphorylation 24 h
post-LPS. The smallest decrease was observed for p38
MAP kinase. These findings suggest that RGD motif-
dependent integrin signaling, involving FAK activation, is
solidly linked to LPS-induced ERK and JNK activations
during the progression of acute lung injury, and that it is
weakly linked to p38 MAP kinase activation.
Involvement of integrin αvβ3 in the inflammatory responses
The findings of the present study suggest the involvements
of RGD motif-dependent integrin binding and integrin
signal activation during the initiation and progression of
LPS-induced lung injury in our mouse model. The RGD
motif binds specifically to αvβ3 integrins expressed on the
surface of macrophages, neutrophils, endothelial cells,
and migrating smooth muscle cells [30,31]. However, no
data is available on the roles of integrin αvβ3 in leukocyte
migration to the lungs or in other pulmonary inflamma-
tory responses. Therefore, we evaluated the involvement
of RGD motif-dependent integrin αvβ3 binding in the key
pulmonary inflammatory responses to LPS treatment
Effects of anti-αv or anti-β3 mAb on LPS-induced increases in inflammatory cell numbers and total protein levels in BAL fluid Figure 7
Effects of anti-αv or anti-β3 mAb on LPS-induced increases in inflammatory cell numbers and total protein lev-
els in BAL fluid. Where indicated, mice were administered anti-αv, anti-β3, or IgG (5 mg/kg, i.p.) once 1 h before LPS treat-
ment and sacrificed 4 h post-LPS. Mice were also administered these mAbs (5 mg/kg, i.p.) once 2 h after LPS and sacrificed 24 h 
post-LPS. Neutrophil (A) and macrophage (B) numbers and total protein levels (C) in BAL fluid. Values represent means ± SEM 
of 5 mice per group. *Significantly different from saline treated controls, p < 0.05; significantly different at 4 h (+) and 24 h (‡) 
post-LPS from animals treated with LPS only, p < 0.05.Respiratory Research 2009, 10:18 http://respiratory-research.com/content/10/1/18
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using a blocking anti-αv or anti-β3 mAb. Anti-αvor anti-β3
(5 mg/kg, i.p., 1 h before LPS) significantly inhibited the
neutrophil number increases in BAL fluid by 50 and 61%
at 4 h post-LPS (p < 0.05), respectively (Figure 7A). Simi-
larly, at 24 h post-LPS, anti-αv or anti-β3 at 2 h after LPS
significantly inhibited neutrophil increases (by 44 and
50%, respectively, p < 0.05) (Figure 7A) and macrophage
increases (by 71 and 60%, respectively, p < 0.05) (Figure
7B).
Moreover, anti-αv (1 h before or 2 h after LPS) signifi-
cantly inhibited LPS-induced BAL protein increases at 4
and 24 h post-LPS by 53 and 80%, respectively (Figure
7C). Interestingly, the inhibitory effect of anti-β3 mAb was
effective only at 4 h post-LPS (59% inhibition), but it was
not effective at 24 h post-LPS (7% inhibition).
LPS-induced increases in TNF-α and MIP-2 levels in BAL
fluid 4 h post-LPS were reduced by anti-αv (by 42 and
39%, respectively) or anti-β3  mAb (by 48 and 60%,
respectively) when administered 1 h before LPS (p < 0.05)
(Figure 8A, 8B). At 24 h post-LPS, TNF-α levels were also
inhibited by posttreatment with anti-αv or anti-β3 (45 and
38% inhibition, respectively) (Figure 8D). Anti-αv or anti-
β3 inhibited LPS-induced MMP-9 activity in BAL fluid at 4
h post-LPS by 87 and 82% and at 24 post-LPS by 73 and
79%, respectively (Figure 8C and 8E).
Discussion
In the present study, we determined: (1) RGDS effectively
inhibited LPS-induced inflammatory cell migration into
the lung, protein accumulation and proinflammatory
mediator production in BAL fluid; (2) RGDS inhibited
LPS-induced activations of integrin signaling and MAP
kinases in lung tissue; (3) anti-αv mAb inhibited LPS-
induced inflammatory cell migration into the lung, pro-
tein accumulation and proinflammatory mediator pro-
duction in BAL fluid; (4) anti-β3 was also effective at
inhibiting LPS-induced inflammatory responses, except
protein leakage.
Small-molecule RGD peptides have been known to pro-
vide specificity as well as high affinity for RGD recogniz-
ing integrins [32]. Previously, RGD-containing synthetic
peptides have been shown to inhibit leukocyte recruit-
ment and inflammatory mediator production in arthritis
[33] and liver injury [8]. However, the effect of synthetic
RGDS peptide on the pulmonary inflammatory responses
is not evaluated. In the present study, we demonstrate that
synthetic RGDS peptide can be used to inhibit pulmonary
inflammatory responses to i.t. LPS. Pre- or posttreatment
with RGDS significantly inhibited neutrophil and alveolar
macrophage numbers in BAL fluid at 4 or 24 h post-LPS.
In addition, the lung histologic findings clearly demon-
strated that RGDS effectively reduced LPS-induced lung
parenchymal infiltration of neutrophils with similar
potency when it was administered before or after LPS. Like
RGDS, anti-αv or anti-β3 mAb blocking of integrin αvβ3
ligation markedly inhibited LPS-induced increases in neu-
trophil and alveolar macrophage numbers in BAL fluid at
4 or 24 h post-LPS. To the best of our knowledge, this pro-
vides first evidence that integrin αvβ3is utilized for migra-
tion to regions of lung inflammation by both cell types.
Since αvβ3 is one of major integrin receptors binding to
the RGD motifs of extracellular matrix (ECM) proteins,
these findings suggest that RGDS specifically inhibits
integrin (αvβ3)-dependent inflammatory cell recruitment
to inflamed pulmonary sites. Moreover, this inhibitory
effect of RGDS is β2integrin-independent, because it does
not block β2 integrins [23].
Another important finding made in the present study was
that pre- or posttreatment with RGDS significantly inhib-
ited LPS-induced increases in total protein in BAL fluid at
4 and 24 h post-LPS. Similarly, pre- or posttreatment with
anti-αv significantly inhibited total protein level increases
in BAL fluid as potent as RGDS at both time points, while
anti-β3 was not effective at 24 h post-LPS. Although BAL
protein is not a very specific way to measure pulmonary
permeability, this discrepancy suggests that prevention of
pulmonary edema and other inflammatory responses,
such as leukocyte migration and inflammatory mediator
production, are regulated by different mechanisms [34],
and that blockade of the αv integrins (e.g. αvβ5 and/or
αvβ6) other than αvβ5 is likely to be responsible for the
protective effects of RGDS on BAL protein accumulation.
Indeed, a blocking antibody against the integrin αvβ5 or
αvβ6 protected development of lung vascular permeability
in different models of acute lung injury [35-37]. Addi-
tional studies are required to identify a physiological role
of β3 integrin in the development of pulmonary edema
during acute lung injury.
The productions of TNF-α and chemokines are essentially
required for early LPS-mediated neutrophil recruitment
and lung damage. Moreover, MMPs, like MMP-9, are
required to allow activated neutrophils to transverse ECM
barriers after adhesion, and to enable transendothelial cell
migration. Therefore, RGDS may protect against LPS-
induced acute lung injury by decreasing the productions
or activities of these proinflammatory mediators. Accord-
ing to this concept, our data indicate RGDS significantly
inhibited LPS-induced TNF-α and MIP-2 productions and
MMP-9 activity in BAL fluid at 4 or 24 h post-LPS.
Although its inhibitory effects on TNF-α production and
MMP-9 activity were more potent in the pretreatment
model compared with the posttreatment model at 24 h
post-LPS, the inhibition was evident when it was admin-
istered 2 h after LPS. Similarly, pre- or posttreatment with
anti-αv or anti-β3 also blocked LPS-induced TNF-α or MIP-Respiratory Research 2009, 10:18 http://respiratory-research.com/content/10/1/18
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2 levels and MMP-9 activity in BAL fluid at 4 or 24 h post-
LPS as potently as RGDS. Our results suggest that the
inhibitory effect of RGDS on LPS-induced these inflam-
matory mediator productions or activity during the devel-
opment of acute lung injury is αvβ3 integrin-dependent.
These proinflammatory mediators are known to be regu-
lated at the transcriptional level by MAP kinase pathways
and nuclear factor kappa B (NF-κB) [38-41]. Previously,
we demonstrated that the RGD motifs of ECM entities
that associate with integrin αvβ3 signaling appears to be
Effects of anti-αv or anti-β3 mAb on LPS-induced TNF-α and MIP-2 productions, and on MMP-9 activity Figure 8
Effects of anti-αv or anti-β3 mAb on LPS-induced TNF-α and MIP-2 productions, and on MMP-9 activity. Where 
indicated, mice were administered anti-αv, anti-β3, or IgG (5 mg/kg, i.p.) once 1 h before LPS treatment and sacrificed 4 h post-
LPS. Mice were also administered these mAbs (5 mg/kg, i.p.) once 2 h after LPS and sacrificed 24 h post-LPS. TNF-α(A, D) and-
MIP-2 (B) productions, and MMP-9 activity (C, E) in BAL fluid. Values represent means ± SEM of 5 mice per group. *Significantly 
different from saline treated controls, p < 0.05;+significantly different from animals treated with LPS only, p < 0.05.Respiratory Research 2009, 10:18 http://respiratory-research.com/content/10/1/18
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involved in NF-κB activation during acute lung injury
[13]. In the present study, we report that integrin signal-
ing-dependent MAP kinase activations are associated with
LPS-induced acute lung injury. The regulation of multiple
cellular events in the context of in vivo LPS stimulation is
complex. Because of the extreme bioactivity of many mol-
ecules (i.e., TNF-α) produced by inflammatory cells [9],
these may affect optimal LPS signaling to MAP kinase acti-
vation correlating with kinetics at many levels. Previously,
we demonstrated the kinetics of LPS-induced phosphor-
ylation of these kinases in lung tissue. MAP kinase phos-
phorylation beginning 2 h after LPS, substantially
increased at 4 h and progressively further increased (JNK
activation), were maintained (ERK activation), or
decreased (p38 MAP kinase activation) for up to 24 h after
LPS [28,29], which concurs with the kinetic results of our
present study. Pre- or posttreatment with RGDS markedly
inhibited LPS-induced phosphorylation of these MAP
kinases in lung tissues at 4 or 24 h post-LPS, although it
was less effective at inhibiting p38 MAP kinase phospho-
rylation 24 h post-LPS. In-line with our in vivo data, LPS
signaling activated the integrin signal that amplifies ERK
and JNK activations in macrophages [42]. Moreover, inhi-
bition of LPS-induced cell adhesion and integrin signaling
by RGD resulted in reductions in these MAP kinase activ-
ities in the order ERK ≈ JNK > p38 MAP kinase [9]. Previ-
ously, we found that inhibition of each of these MAP
kinases reduced the LPS-induced proinflammatory medi-
ator productions during acute lung injury [28,29]. Fur-
thermore, inhibition of these kinases, except ERK, reduced
LPS-induced phosphorylation and degradation of IκB-α
and NF-κB activation. Collectively, these findings suggest
that the specific inhibition of integrin signaling by RGDS
results in suppression of proinflammatory mediator pro-
ductions through the MAP-kinase leading to NF-κB path-
way or each different pathway.
Integrin-mediated adhesion and/or clustering led to
enhance the tyrosine phosphorylation of Src tyrosine
kinases and FAK [43-45], and this pathway activates the
classic Ras-MEK-ERK cascade [46]. We do suggest the
involvement of a pathway initiated by FAK activation
through integrin (αvβ3) signaling during LPS-induced
acute lung injury, because RGDS suppressed LPS-induced
FAK phosphorylation in lung tissue and fibrinogen bind-
ing activity in alveolar macrophages. Indeed, anti-αv or
anti-β3 mAb inhibited LPS-induced c-Src and FAK activa-
tion during acute lung injury [13]. Integrin-FAK-ERK/-JNK
pathways have been documented in other in vitro systems
[47-49].
Conclusion
The present study suggests that RGDS inhibits integrin
(αvβ3)-dependent induction of inflammatory cell migra-
tion into the lungs, and proinflammatory mediator pro-
duction. Our data also suggest that the protective effect of
RGDS on pulmonary leakage is αv-dependent, but not β3.
Importantly, posttreatment with RGDS was also highly
effective at reducing these inflammatory responses corre-
lated with its inhibitory effect on integrin signaled MAP
kinase pathways. In addition, blockading the integrin-
FAK-MAP kinase pathway with RGDS may reduce lung
injury progression. Since RGDS has high specificity for
αvintegrins and the in vivo efficacy to access target cells as
a small-molecule [8,32,50], it may effectively attenuate
inflammatory cascade during LPS-induced development
of acute lung injury.
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